Brokerages Set Carisma Therapeutics, Inc. (NASDAQ:CARM) Price Target at $4.94

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) have been given a consensus recommendation of “Hold” by the seven analysts that are currently covering the company, MarketBeat reports. Five analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $4.94.

A number of analysts have recently commented on CARM shares. Baird R W cut shares of Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 12th. Robert W. Baird lowered Carisma Therapeutics from an “outperform” rating to a “neutral” rating and cut their price objective for the stock from $10.00 to $1.00 in a research note on Thursday, December 12th. BTIG Research lowered Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 10th. Evercore ISI reiterated an “in-line” rating and set a $0.70 price target (down from $4.00) on shares of Carisma Therapeutics in a research report on Wednesday, December 11th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Carisma Therapeutics in a research report on Monday, December 16th.

Carisma Therapeutics Stock Down 2.2 %

Carisma Therapeutics stock opened at $0.40 on Tuesday. The stock has a market capitalization of $16.74 million, a PE ratio of -0.26 and a beta of 1.56. The business has a 50 day simple moving average of $0.46 and a 200-day simple moving average of $0.77. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.23 and a quick ratio of 3.23. Carisma Therapeutics has a 12 month low of $0.38 and a 12 month high of $2.77.

Institutional Investors Weigh In On Carisma Therapeutics

Hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC grew its stake in shares of Carisma Therapeutics by 11.9% in the 4th quarter. Renaissance Technologies LLC now owns 231,357 shares of the company’s stock valued at $97,000 after buying an additional 24,600 shares during the period. Barclays PLC lifted its holdings in Carisma Therapeutics by 3,661,933.3% in the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after acquiring an additional 549,290 shares during the last quarter. Finally, Wexford Capital LP grew its position in Carisma Therapeutics by 75.5% in the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after acquiring an additional 15,000 shares during the period. Hedge funds and other institutional investors own 44.27% of the company’s stock.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.